Skip to main content
Article
Estimation of radiation dose to red marrow in myeloablative 131I-BC8 (anti-CD45) radioimmunotherapy for high-risk myelodysplastic syndrome and advanced AML: Sacrum vs acetabulum
The Journal of Nuclear Medicine (2010)
  • Joseph Rajendran, University of Washington Medical Center
  • Andrew Shields, University of Washington Medical Center
  • Darrell Fisher, Pacific Northwest National Laboratory
  • John Pagel, Fred Hutchinson Cancer Research Center
  • Ajay Gopal, Seattle Cancer Care Alliance
  • Lawrence Durack, University of Washington
  • Frederick Appelbaum, Fred Hutchinson Cancer Research Center
  • Oliver Press, Fred Hutchinson Cancer Research Center
Publication Date
May, 2010
Citation Information
Joseph Rajendran, Andrew Shields, Darrell Fisher, John Pagel, et al.. "Estimation of radiation dose to red marrow in myeloablative 131I-BC8 (anti-CD45) radioimmunotherapy for high-risk myelodysplastic syndrome and advanced AML: Sacrum vs acetabulum" The Journal of Nuclear Medicine Vol. 51 Iss. supplement 2 305 (2010) p. 305
Available at: http://works.bepress.com/john-pagel/194/